ClinicalTrials.gg
CompletedNCT02949024HULKUpdated May 13, 2021Results posted

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

A Phase 1/2 interventional study of IVT Aflibercept and SC CLS-TA in Diabetic Macular Edema, sponsored by Clearside Biomedical, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-13.

Sponsored by Clearside Biomedical, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,022 studies in Diabetes Mellitus with a site in United States — 288 open to participants now, 389 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
2,023rd of 2,501
20 · median 82
Started
2016
with 124 others
Phase 1/2
58 of 3,022
5 open now
Registered
1,973rd of 3,022
by date

Among the 3,022 studies in Diabetes Mellitus with a site in United States, this one is the 2,023rd largest by enrollment of the 2,501 interventional ones that give a count, is one of 125 that started in 2016, is one of 58 in phase 1/2, and was the 1,973rd registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

288 of the 3,022 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

283 more — sign in →

All 288 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,022 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

This study is designed to demonstrate the safety and tolerability of suprachoroidal CLS-TA alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.

Read the detailed description

This is a Phase 1/2, multicenter, open-label study in subject with DME associated with diabetes mellitus.

Subjects will be screened and if eligible, will be assigned to study arm at the Baseline Visit (Visit 1, Day 0).

Following the Baseline Visit, subjects will participate in six monthly follow-up visits (Visit 2-7; Weeks 4-24) for safety and efficacy assessments and to determine whether additional therapy is needed based upon pre-defined criteria.

03

Conditions studied

  • Diabetic Macular Edema

Keywords

  • Diabetes mellitus
  • Diabetic retinopathy
  • Microneedle
  • Microinjection
  • Triamcinolone
  • Choroid
  • Choroid Injection
  • Aflibercept
  • Suprachoroidal
  • Triamcinolone acetonide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women ≥ 18 years of age with type 1 or type 2 diabetes mellitus
  • DME with central involvement (>320 microns in the central subfield on SD-OCT) in the study eye
  • ETDRS BCVA letter score of 83 to 14, inclusive (Snellen equivalent of 20/25 to 20/500) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Evidence of DME due to any other cause other than diabetes mellitus in the study eye
  • PRP or focal laser photocoagulation in the study eye within 90 days of screening
  • Intraocular pressure ≥ 22 mmHg or uncontrolled glaucoma (open angle or angle closure) in the study eye
  • History of any previous ophthalmic surgeries in the study eye within 90 days of screening
  • High risk PDR in the study eye, for whom enrollment into the study, in the principal investigator's opinion would put the eye at undue risk for vision loss
  • Any previous treatment in the study eye with ILUVIEN implant
  • Previous treatment for DME in the study eye (TX naive arm only); treatment in the study eye for DME greater than 1 year prior to screening can be considered as treatment naive, at the investigator's discretion
  • Subjects previously treated for DME cannot have been treated in the study eye with an intravitreal injection of anti-VEGF or periocular within 90 days prior to screening (Previous TX arm only)
  • Subjects previously treated for DME cannot have been treated in the study eye with intraocular corticosteroids within 6 months prior to screening (Previous TX arm only)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    TX Naïve Arm

    Treatment in the TX Naive arm will consist of one unilateral injection of IVT aflibercept in combination with one unilateral injection of SC CLS-TA in the same eye.

    Drug: IVT Aflibercept · Drug: SC CLS-TA

  • Experimental
    Previous TX Arm

    Treatment in the Previous TX arm of the study will consist of one unilateral injection of SC CLS-TA.

    Drug: SC CLS-TA

Interventions

  • IVT aflibercept \[2 mg (50 µL)\]

    Also known as: Aflibercept

  • \[4 mg (100 µL)\]

    Also known as: Triamcinolone Acetonide

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

    Number of participants with treatment emergent adverse events and serious adverse events reported over 6 months of follow-up

    Time frame: Over 6 months of follow-up

Secondary outcomes

  1. Mean Change From Baseline in Intraocular Pressure

    Baseline and change from baseline at 6 months in intraocular pressure as measured by applanation tonometry

    Time frame: Baseline and 6 months

  2. Mean Change From Baseline in Central Subfield Thickness

    Baseline and change from baseline at 6 months in central subfield thickness. Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

    Time frame: Baseline and 6 months

  3. Best Corrected Visual Acuity

    Baseline and Change from baseline at 6 months in best corrected visual acuity before and after treatment Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured as the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

    Time frame: Baseline and 6 months

  4. CLS-TA Injections

    After the initial treatment with CLS-TA, with or without intravitreal aflibercept, at Baseline, retreatment with CLS-TA was allowed in either treatment group from Month 2 through Month 6 if pre-defined retreatment criteria were met. Number of patients receiving 0, 1, 2, 3, 4 or 5 retreatments with CLS-TA.

    Time frame: 2 to 6 months following initial treatment with study drug

07

Results

Posted Apr 19, 2021

Participant flow

Participant flow — Overall Study
MilestoneTX Naïve ArmPrevious TX Arm
Started1010
Completed109
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events and Serious Adverse Events

Number of participants with treatment emergent adverse events and serious adverse events reported over 6 months of follow-up

Time frame:
Over 6 months of follow-up
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events and Serious Adverse Events
ParticipantsTX Naïve ArmPrevious TX Arm
Number of participants with treatment emergent adverse events89
Number of participants with serious adverse events00
SecondaryMean Change From Baseline in Intraocular Pressure

Baseline and change from baseline at 6 months in intraocular pressure as measured by applanation tonometry

Time frame:
Baseline and 6 months
Reported as:
Mean · mm Hg
Mean Change From Baseline in Intraocular Pressure
mm HgTX Naïve ArmPrevious TX Arm
Baseline14.2 ± 3.5213.3 ± 2.50
Month 6-0.3 ± 2.412.8 ± 7.89
SecondaryMean Change From Baseline in Central Subfield Thickness

Baseline and change from baseline at 6 months in central subfield thickness. Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.

Time frame:
Baseline and 6 months
Reported as:
Mean · Microns
Mean Change From Baseline in Central Subfield Thickness
MicronsPrevious TX ArmTX Naïve Arm
Baseline421.6 ± 94.33472.7 ± 109.46
Month 6-90.9 ± 62.48-119.6 ± 65.48
SecondaryBest Corrected Visual Acuity

Baseline and Change from baseline at 6 months in best corrected visual acuity before and after treatment Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured as the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.

Time frame:
Baseline and 6 months
Reported as:
Mean · Letters
Best Corrected Visual Acuity
LettersTX Naïve ArmPrevious TX Arm
Baseline67.2 ± 11.6667.2 ± 8.95
Month 68.5 ± 11.961.1 ± 11.94
SecondaryCLS-TA Injections

After the initial treatment with CLS-TA, with or without intravitreal aflibercept, at Baseline, retreatment with CLS-TA was allowed in either treatment group from Month 2 through Month 6 if pre-defined retreatment criteria were met. Number of patients receiving 0, 1, 2, 3, 4 or 5 retreatments with CLS-TA.

Time frame:
2 to 6 months following initial treatment with study drug
Reported as:
Count of participants · Participants
CLS-TA Injections
ParticipantsTX Naïve ArmPrevious TX Arm
0 additional injections41
1 additional injection23
2 additional injections02
3 additional injections20
4 additional injections24

Adverse events

Collected over 6 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TX Naïve Arm0/10 (0%)0/10 (0%)8/10 (80%)
Previous TX Arm0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTX Naïve ArmPrevious TX Arm
CataractEye disorders3/102/10
Conjunctival haemorrhageEye disorders3/102/10
CataractEye disorders2/100/10
HeadacheNervous system disorders1/102/10
Dry eyeEye disorders0/101/10
Dry eyeEye disorders0/101/10
EpiscleritisEye disorders0/101/10
Eye irritationEye disorders1/100/10
Eye irritationEye disorders1/100/10
Eye painEye disorders0/101/10

Baseline characteristics

The Intent-to-treat population included all subjects who received study treatment.

Age, Categorical
Age, Categorical(Participants)TX Naïve ArmPrevious TX ArmTotal
<=18 years000
Between 18 and 65 years5611
>=65 years549
Age, Continuous
Age, Continuous(Years)TX Naïve ArmPrevious TX ArmTotal
Mean61.9 ± 7.2863.1 ± 8.3162.5 ± 7.63
Sex: Female, Male
Sex: Female, Male(Participants)TX Naïve ArmPrevious TX ArmTotal
Female448
Male6612
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TX Naïve ArmPrevious TX ArmTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American224
White6612
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)TX Naïve ArmPrevious TX ArmTotal
United States101020
Baseline Best Corrected Visual Acuity
Baseline Best Corrected Visual Acuity(Letters)TX Naïve ArmPrevious TX ArmTotal
Mean67.2 ± 11.6667.2 ± 8.9567.2 ± 10.12
08

Study locations

2 sites
  • Retina Vitreous Associates Medical Group Inc
    Mountain View, California 94040, United States
  • Retina Consultants of Houston, PA
    The Woodlands, Texas 77384, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Oct 2017, 11 months.

Results were first posted in Apr 2021, 3 years 6 months after primary completion. A results delay was requested in May 2018.

Of 40 phase 1/2 interventional studies under Diabetes Mellitus, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 60. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2016
First posted
Oct 31, 2016
StartActual
Nov 10, 2016
Primary completionActual
Oct 17, 2017
CompletionActual
Oct 17, 2017
Results delay requested
May 7, 2018
Results first posted
Apr 19, 2021
Last update
May 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02949024
Lead sponsor
Clearside Biomedical, Inc.
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Nov 10, 2016
Primary completion
Oct 17, 2017
Completion
Oct 17, 2017
Results posted
Apr 19, 2021
Last update
May 13, 2021

Study contacts

Thomas Ciulla, MD MBA
study director · Clearside Biomedical, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion